1677 results about "Chemo therapy" patented technology

The invention relates to the technical field of medical data processing and prediction, and discloses a chemotherapy adverse reaction prediction and intervention system based on big data. The system integrates an unstructured disease course text and structured inspection data of a patient, generates a time-series symptom event, and performs time window alignment and fusion on the time-series symptom event, a medication record and a physical sign monitoring stream to form a multi-dimensional time-series data block. The system is combined with an external medical knowledge base to construct a dynamic association network among symptoms, medicines and physiological indexes, and dynamically calculates the confidence coefficient of an adverse reaction mode according to real-time data. By using a predictive model of the timing attention mechanism, the system can output a continuous curve of patient risk over time. The system automatically matches and generates a personalized intervention instruction sequence containing specific measures and execution time windows according to key time points and modes when the risk curve exceeds a threshold value. According to the invention, dynamic and advanced early warning and accurate intervention of adverse reaction risks of chemotherapy are realized.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

The invention provides a tumor treatment effect prediction method based on multi-modal data, and relates to the field of medical artificial intelligence. The method comprises the following steps: collecting magnetic resonance image data, histopathological section images and clinical baseline data of a tumor patient and a treatment response evaluation record after neoadjuvant chemotherapy; the collected image information is preprocessed; feature extraction is carried out based on the preprocessed image information; screening a feature subset with the highest prediction value from the extracted features; constructing a radiopathomics fusion model by using the feature subset with the highest prediction value; evaluating the radiopathomics fusion model; and predicting the tumor treatment effect by using the evaluated radiopathomics fusion model. The problems that an existing tumor neoadjuvant chemotherapy (NACT) curative effect prediction method is low in accuracy, poor in generalization ability, lack of multi-modal data fusion and insufficient in model interpretability are solved.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The application describes the first-in-human study on using a anti-KLK2xCD3 bispecific antibody and another anti-cancer drug, in particular, in particular a taxane chemotherapy or Androgen Receptor Pathway Inhibitor (ARPI), to provide enhanced antitumor efficacy with a deeper and more durable clinical response.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

The invention relates to a breast cancer cardiotoxicity risk prediction system based on multi-modal data fusion. According to the system, multi-source heterogeneous medical data such as electronic health records, dynamic electrocardiogram monitoring, echocardiography video streams, chemotherapy medication time sequence data and pathological section images are collected in real time through a distributed architecture, and the storage efficiency is optimized by adopting a layered compression strategy. According to the system, risk indexes are mapped to a three-dimensional heart thermodynamic diagram, key feature contribution degrees are displayed in an associated manner, and a dynamic risk knowledge map is established to reveal a toxicity generation path. The system deploys an incremental learning mechanism to realize continuous optimization of the model, guarantees data security through differential privacy and federal learning, sets a real-time early warning feedback loop, triggers clinical intervention when the risk exceeds a threshold value, and dynamically adjusts the weight of the model according to the feedback of a physician, thereby remarkably improving the prediction accuracy and clinical applicability.

The invention discloses a breast cancer neoadjuvant chemotherapy curative effect prediction method and system, and relates to the medical image processing and analysis technology, and the method comprises the steps: carrying out the Macenko dyeing normalization of a sample HE pathological image of a patient; extracting a tissue region from the normalized sample HE pathological image by using an HEST method; inputting the extracted tissue region into a Prov-GigaPath network, extracting a feature vector of a specified dimension under set parameters, and performing dimension reduction on the extracted feature vector; inputting the feature vectors subjected to dimension reduction into an ABMIL model, and training the feature vectors; and predicting the HE pathological image of the patient based on the trained ABMIL model, and visualizing the prediction result by using the attention score of the trained ABMIL model. According to the method provided by the invention, multi-level complex features such as cellular morphology and tissue structure in the HE image can be automatically mined, and the accuracy and reliability of prediction are greatly improved.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The invention provides a nano-drug based on atomic layer deposition and a preparation method of the nano-drug, mesoporous silica is taken as a carrier, bimetallic nanoparticles are precisely deposited through ALD, and chemotherapeutic drugs and antibacterial components are loaded by combining amination and targeted PEG modification, so that the following functions are realized: (1) H2O2 in a tumor microenvironment is catalyzed to generate reactive oxygen species (ROS); removing fusobacterium nucleatum and damaging a biological membrane of the fusobacterium nucleatum; (2) GSH is consumed through Fenton reaction, and tumor drug resistance is reversed; and (3) the drug is released in pH response, and tumor cells are accurately killed. The invention further provides application of the nano-drug based on atomic layer deposition in treatment of related drug-resistant colorectal cancer induced by fusobacterium nucleatum, the process is controllable, the biocompatibility is excellent, the treatment effect on the drug-resistant colorectal cancer is remarkably improved, and the nano-drug has wide clinical application prospects.

Chemotherapeutic Combinations The present disclosure relates to novel combinations of bifunctional molecules that contain a BRD9 binding ligand with at least one chemotherapeutic agent. The novel combinations are useful in the treatment of cancer.

The invention relates to the technical field of disease curative effect evaluation, and discloses a method for evaluating the curative effect of granulocyte deficiency accompanying fever after hematologic tumor chemotherapy based on machine learning, and the method comprises the steps: S1, collecting and preprocessing multi-center medical data, the data comprising structured clinical data and multi-modal unstructured data; s2, a curative effect prediction model is constructed based on a graph neural network, and a central moment constraint-based graph federal learning training model is adopted, wherein a patient graph is constructed as an original graph and an enhanced graph is generated; respectively processing the original image and the enhanced image through a two-channel image convolutional neural network, and extracting a high-order representation vector; constructing an enhanced perception loss function based on the high-order representation vectors of the original image and the enhanced image; combining a federated learning framework with multi-center data to train a model; and S3, predicting a curative effect evaluation result through the trained curative effect prediction model. The accuracy, the stability and the clinical interpretability of curative effect evaluation are improved.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention belongs to the field of biological medicine, and particularly relates to phase separation polypeptide and a preparation method and application thereof. The structure of the phase separation polypeptide is shown as a formula (I). According to the polypeptide compound provided by the invention, liquid-liquid phase separation can be carried out to form condensed liquid drops, and DNA damage response proteins are enriched and separated in cells. The polypeptide compound disclosed by the invention is simple in synthesis method and good in biocompatibility, and liquid-liquid phase separation can be carried out; dNA damage response protein can be captured in cells, DNA repair is interfered, and the tumor radiotherapy effect is enhanced. Therefore, the polypeptide compound provided by the invention can be used for tumor radiotherapy, chemotherapy and other treatment methods.

The invention relates to a double-framework self-developing embolism system based on iodine modified PNIPAM gel and cross-linked albumin microspheres, which simulates a brick wall-concrete effect through a microsphere-gel composite structure and synergistically improves the embolism strength. A novel TACE treatment system is designed and constructed, multiple effects of tracing, embolism, hypoxia enhanced chemotherapy and tumor microenvironment improvement are achieved through the self-developing temperature-sensitive gel-drug carrying microspheres, and the anti-tumor effect is cooperatively improved.

The invention discloses DLL3 serving as a cervical neuroendocrine cancer treatment target and application of the DLL3, and belongs to the technical field of biology. The invention discloses specific expression of a DLL3 gene in cervical neuroendocrine carcinoma (NECC) and application of the DLL3 gene as a therapeutic target. Single cell sequencing and immunohistochemistry find that a DLL3-NOTCH1 / 2 signal axis is activated in NECC, and functional experiments prove that the DLL3-NOTCH1 / 2 signal axis drives malignant progression by promoting tumor proliferation and inducing T cell depletion. In addition, the invention also constructs an NECC organ-TILs co-culture model, and verifies the synergistic effect of the DLL3 targeted drug AMG757 combined with EP chemotherapy. The invention provides new target selection and theoretical basis for precise diagnosis and treatment of NECC, and has important clinical transformation value.

The invention belongs to the technical field of medicines, and provides a novel method for overcoming multidrug resistance of tumors based on innate immune regulation. The invention relates to an application of an agonist of an innate immune STING pathway and an ENPP1 inhibitor in overcoming multidrug resistance of tumors and enhancing an anti-tumor curative effect. The STING agonist or the ENPP1 inhibitor is combined with an anti-tumor chemical drug for application, so that the effects of overcoming the multi-drug resistance of chemotherapeutic drugs and enhancing the anti-tumor curative effect are achieved. The STING agonist / or ENPP1 inhibitor has the effect of reversing multidrug resistance of tumors, and can enhance the sensitivity of cancer cells to chemotherapeutic drugs and monoclonal antibody drugs, so that the curative effect of antitumor drugs is enhanced, and the STING agonist / or ENPP1 inhibitor is expected to be developed into a novel reversal agent drug for multidrug resistance tumors. The novel anti-multidrug resistance strategy provides a new thought for drug design and cancer treatment, and has a great application prospect in clinical treatment of cancers.

The invention discloses a preparation method of a polymer vesicle capable of crossing a blood brain barrier, and belongs to the field of high polymer materials and medical engineering. The preparation method of the polymer vesicle capable of crossing the blood brain barrier comprises the following steps: synthesizing an amphiphilic block copolymer by utilizing ring-opening polymerization reaction of polycaprolactone and anhydride in an amino acid ring, then assembling the polymer into the polymer vesicle, and modifying a monoclonal antibody of a transferrin receptor on a polypeptide chain. The polymer vesicle prepared by the invention is simple and convenient in preparation process, short in period, good in stability, good in biocompatibility and good in biodegradability, can be used as an excellent carrier of chemotherapeutic drugs, and can effectively realize drug delivery of targeting brain tumor cells across a blood brain barrier. Compared with a commercial drug delivery carrier, the polymer vesicle has the advantage that the permeability of the drug in a bionic blood brain barrier and the targeted uptake rate of brain tumor cells are remarkably improved.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The composition comprises an IGF2BP3 inhibitor and a platinum chemotherapeutic drug. According to the combined medication scheme, the IGF2BP3 function is inhibited to block an ATF4 survival promoting signal channel mediated by the IGF2BP3 function, a synergistic effect is generated with a DNA damage mechanism of platinum drugs, the anti-tumor effect can be remarkably enhanced, chemotherapy drug resistance can be effectively reversed, toxic and side effects are expected to be reduced, and the application prospect is wide. And a new strategy is provided for overcoming the treatment problem of the non-small cell lung cancer, especially platinum-resistant non-small cell lung cancer.

The invention relates to the technical field of medical care, in particular to a lung cancer chemotherapy patient resilience intervention system and application thereof. According to the intervention system based on the PERMA mode, intervention is implemented in stages through comprehensive measures such as acute symptom management, psychological construction strengthening, chemotherapy adverse reaction cognition, home nursing skill training, physical recovery training, social support linkage and treatment compliance improvement. The method comprises the following steps: quantifying pain by using digital scoring equipment, and assisting pressing to relieve symptoms by using acupoint diagrams; the psychological toughness is enhanced through the positive voice listening and the anti-cancer brave diary recording; an online and offline combined mode is adopted, group lectures, scene simulation video teaching and online community interaction are carried out, and social support of patients is enhanced; personalized exercise prescriptions and home safety lists are formulated, and treatment compliance is improved. The system can significantly improve the recovery of a patient, improve the life quality during chemotherapy, and provide a scientific basis for innovation of a tumor nursing mode.

The invention discloses a symmetric nucleoside microneedle patch loaded with polymer vesicles as well as a preparation method and application of the symmetric nucleoside microneedle patch. The symmetric nucleoside microneedle patch loaded with the polymer vesicles comprises a guanosine-quadruplex hydrogel microneedle tip doped with drug-loading polymer vesicles, the raw material of the drug-loaded polymer vesicle comprises a polycaprolactone-polyglutamic acid copolymer; the guanosine-quadruplex hydrogel is prepared from the following raw materials: guanosine and KB (OH) 4. The microneedle patch is constructed on the basis of dynamic covalent bond and non-covalent interaction, has a sharp tip array capable of penetrating the epithelium and the lower layer of a mucous membrane, can efficiently deliver a drug to a canker lesion part by bypassing a mucous membrane barrier, can be controllably broken under a high ROS condition of an inflammation microenvironment, has the characteristics of high drug delivery efficiency and high accuracy, and can be used for preparing a medicine for treating the canker lesion part. The effect of effectively improving chemotherapy-induced oral ulceration can be achieved by reducing inflammatory response, relieving pain feeling and inhibiting pain sensitization.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention discloses an EGFR (epidermal growth factor receptor) targeted nano-drug carrier and a preparation method thereof, the EGFR targeted nano-drug carrier comprises drug-loading nanoparticles, an erythrocyte membrane coating the drug-loading nanoparticles and GE11 peptide connected to the erythrocyte membrane, and the drug-loading nanoparticles are formed by connecting tannic acid, ellagic acid and 1, 4-phenyldiboronic acid through boric acid ester bonds. The EGFR targeted nano-drug carrier disclosed by the invention can be enriched at an EGFR overexpressed tumor site in a targeted manner, and can be effectively prevented from being cleared by an immune system, and the drug loaded by the drug-loaded nanoparticles is released in a high-active oxygen environment, so that the treatment effect on tumors can be improved, and the toxic and side effects on normal tissues can be reduced; and photothermal therapy and chemotherapy effects can be simultaneously generated under NIR illumination, and the anticancer efficiency can be remarkably improved through the synergistic effect of the photothermal therapy and the chemotherapy.

The invention provides a medical oncology chemotherapy nursing system, and relates to the field of medical data processing, and the system comprises an information obtaining module which is used for obtaining chemotherapy related information of a chemotherapy patient; the physical sign monitoring module is used for acquiring vital sign information of a chemotherapy patient and generating first nursing risk information; the biochemical monitoring module is used for determining key biochemical indexes, collecting biochemical detection information and generating second nursing risk information based on chemotherapy related information; the comprehensive detection module is used for determining a key comprehensive detection item based on the chemotherapy related information, acquiring detection information of the key comprehensive detection item and generating third nursing risk information; the emotion monitoring module is used for acquiring voice information and sleep information of the chemotherapy patient and generating emotion risk information; the nursing prompting module is used for generating nursing prompting information based on the first nursing risk information, the second nursing risk information, the third nursing risk information and the emotion risk information, and the chemotherapy nursing system has the advantage of improving the quality of chemotherapy nursing.

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.

The invention relates to the field of biology, and provides a human immortalized pancreatic cancer fibroblast as well as a preparation method and application thereof.The human immortalized pancreatic cancer fibroblast comprises three cell strains which are all primary fibroblast cells extracted from tumor tissues of pancreatic ductal adenocarcinoma patients, the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are classified and named as the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 respectively, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are all Cell STR identification and immunofluorescence detection prove that the cell strain is a fibroblast cell strain. After the tumor-associated fibroblast and pancreatic cancer cells are co-cultured, the proliferation ability of the tumor cells is obviously enhanced, and the sensitivity of the tumor cells to a chemotherapeutic drug gemcitabine is reduced. A new thought is provided for diagnosis and treatment of pancreatic cancer, and based on the pancreatic cancer in-vitro co-culture model established in vitro, the application has important significance for researching the effect and related mechanisms of fibroblasts in the pancreatic cancer tumor microenvironment.

The invention relates to a double-cavity radiotherapy and chemotherapy integrated treatment capsule for brain glioma, which aims to solve the problems that the existing radioactive seed source or chemotherapy carrier cannot give consideration to radiotherapy and chemotherapy, the dosage is difficult to regulate and control, the medicine distribution is non-uniform and the like. The brain glioma double-cavity radiotherapy and chemotherapy integrated treatment bag is composed of a radiotherapy pipeline and a chemotherapy pipeline, the whole integrated treatment bag is a spiral pipe body, the radiotherapy pipeline is located in an inner ring, the chemotherapy pipeline is located in an outer ring, the radiotherapy pipeline is a closed cavity, a liquid radioactive source is contained in the closed cavity, and the liquid radioactive source is located in an outer ring. The chemotherapy medicine is released from the head end of the chemotherapy pipeline, the chemotherapy medicine is injected from the tail end of the chemotherapy pipeline, and the surface of the integrated treatment bag is coated with a composite antibacterial layer. According to the integrated treatment capsule, radiopharmaceuticals and chemical drugs are placed in the inner cavity and the outer cavity respectively, synergistic treatment of radiotherapy and chemotherapy is achieved through the synchronous effect of the two channels, and long-term low-dose release of the radiopharmaceuticals and the chemotherapy drugs is achieved and toxic and side effects are reduced by adjusting the screw pitch and the thickness of the tube wall.

Disclosed in the present invention is a probiotic. The probiotic comprises Parabacteroides distasonis with the microbial deposit number of CCTCC NO: M20222033, Limosilactobacillus fermentum with the microbial deposit number of CCTCC NO: M2023352, Lactobacillus salivarius with the microbial deposit number of CCTCC NO: M2023348, Enterococcus avium with the microbial deposit number of CCTCC NO: M2023350, and Bifidobacterium bifidum with the microbial deposit number of CCTCC NO: M2023349. The probiotic has good safety, has antioxidant activity, can inhibit pathogenic bacteria, can alleviate colon injury, can inhibit inflammation, and can alleviate diarrhea caused by chemotherapeutic drugs.

The invention relates to the technical field of medical image processing and interventional therapy assistance, and discloses an intubation fluorescent image feature learning system for hepatic artery chemoembolization. Comprising an image acquisition module which is configured to acquire a distortionless two-dimensional fluorescent blood vessel image in a hepatic artery chemoembolization super-selective intubation process; the control module is used for extracting surface geometric features of the blood vessel from the two-dimensional fluorescent blood vessel image; inputting the surface geometric features to a preset spatial reasoning model, and outputting a spatial distribution probability matrix of each blood vessel part; capturing a difference signal between the spatial distribution probability matrix and angiography feedback data in an actual intubation process in real time, and forming an iterative training data set to optimize the spatial reasoning model; and identifying a potential complex blood vessel region according to the spatial distribution probability matrix, generating an intubation path early warning signal, and generating guide parameters of X-ray release opportunity and dose based on the early warning signal so as to reduce radiation exposure.